|
|
所有人群 |
MV |
NMV |
|
使用升压 |
不使用的升压 |
|
|
| N(%) |
336年 |
83 (24.7) |
253 (75.3) |
|
108 (32.1) |
228 (67.9) |
|
| 年龄(岁) |
76 (61、84) |
78 (67、84) |
76 (61、84) |
0.584 |
78 (66、87) |
75 (61、83) |
0.065 |
| 男,n(%) |
213 (63.4) |
54 (60.7) |
159 (64.4) |
0.535 |
71 (65.7) |
142 (62.3) |
0.539 |
| 并发症,n(%) |
|
|
|
|
|
|
|
| 慢性阻塞性肺病 |
40 (11.9) |
14 (15.7) |
26日(10.5) |
0.194 |
15 (13.9) |
25 (11.0) |
0.440 |
| CDVD |
48 (14.3) |
14 (15.7) |
34 (13.8) |
0.650 |
18 (16.7) |
30 (13.2) |
0.391 |
| CBVD |
88 (26.2) |
20 (22.5) |
68 (27.5) |
0.352 |
30 (27.8) |
58 (25.4) |
0.649 |
| 糖尿病 |
77 (22.9) |
15 (16.9) |
62 (25.1) |
0.112 |
35 (32.4) |
42 (18.4) |
0.004 |
| CRD |
30 (8.9) |
9 (10.1) |
21日(8.5) |
0.648 |
12 (11.1) |
18 (7.9) |
0.334 |
| HBD |
24 (7.1) |
6 (6.7) |
18 (7.3) |
0.864 |
4 (3.7) |
20 (8.8) |
0.092 |
| 健康的 |
28日(8.3) |
7 (7.9) |
21日(8.5) |
0.852 |
5 (4.6) |
23日(10.1) |
0.091 |
| 实验室结果 |
|
|
|
|
|
|
|
| 白细胞(×109/ L) |
10.0 (6.7,14.1) |
10.4 (6.7,15.8) |
9.7 (6.8,13.9) |
0.244 |
10.8 (6.9,16.0) |
9.8 (6.6,13.9) |
0.180 |
| 血红蛋白(g / L) |
126 (115、137) |
126 (115、137) |
126 (116、137) |
0.781 |
126 (113、136) |
127 (117、138) |
0.314 |
| HCT (%) |
36.9 (31.8,40.8) |
35.4±9.2 |
37.2 (32.7,40.7) |
0.356 |
34.9±9.1 |
37.3 (32.9,40.9) |
0.092 |
| PLT (×109/ L) |
184 (131、251) |
155 (117、241) |
192 (141、251) |
0.109 |
162 (123、245) |
193 (141、252) |
0.082 |
| 铝青铜(g / L) |
36.2 (32.1,39.1) |
34±6 |
36.7 (32.8,39.3) |
0.002 |
34.2±5.7 |
36.8 (33.0,39.4) |
< 0.001 |
| 克雷亚(μ摩尔/升) |
80.5 (60.8,114.3) |
92.5 (71.2,149.2) |
75.5 (59.9,104) |
< 0.001 |
92 (69,145.4) |
101.4 75.4(60岁) |
< 0.001 |
| 包子(更易/ L) |
7.4 (5.3,11.0) |
9.5 (6.5,15.0) |
6.8 (5.0,10.3) |
< 0.001 |
9.0 (6.0,13.6) |
6.8 (5.1,10.0) |
< 0.001 |
| AST (U / L) |
30 (20,56) |
36 (81) |
29(20日,53) |
0.097 |
33 (75) |
29(20日,53) |
0.122 |
| ALT (U / L) |
20 (37) |
17 (45) |
21 (36) |
0.694 |
18日(12日40) |
21 (37) |
0.220 |
| 治疗组(μ摩尔/升) |
14.8 (9.6,23.0) |
16.1 (10.6,25) |
14日(9.5,22.3) |
0.164 |
16.0 (10.2,25.9) |
13.9 (9.5,21.9) |
0.089 |
| DBIL (μ摩尔/升) |
6.4 (4.0,10.6) |
7 (4.4,12.3) |
6.1 (3.9,9.7) |
0.037 |
7.0 (4.4,12.0) |
6.0 (3.8,9.6) |
0.020 |
| K+(更易/ L) |
3.8 (3.5,4.2) |
4 (3.6,4.5) |
3.8 (3.5,4.1) |
0.006 |
4.0 (3.5,4.3) |
3.8 (3.5,4.2) |
0.220 |
| PaO2/ FiO2 |
303 (262、352) |
285 (244、326) |
313 (272、363) |
< 0.001 |
287 (246、333) |
315 (274、363) |
0.002 |
| 生命体征 |
|
|
|
|
|
|
|
| SBP(毫米汞柱) |
132 (119、139) |
122 (100、135) |
134 (125、143) |
< 0.001 |
113 (97、133) |
135 (126、145) |
< 0.001 |
| 菲律宾(毫米汞柱) |
68 (65、76) |
65 (71) |
70 (66、78) |
< 0.001 |
62 (69) |
72 (68、78) |
< 0.001 |
| 人力资源(次/分钟) |
86 (78、94) |
86 (79、104) |
86 (78、94) |
0.033 |
89 (79、106) |
86 (78、92) |
< 0.001 |
| 严重程度评分 |
|
|
|
|
|
|
|
| CURB65 |
2 (2、3) |
3 (3、4) |
2 (1、3) |
< 0.001 |
3 (2.5 4) |
2 (1、3) |
< 0.001 |
| CRB65 |
2 (1、3) |
3 (2、3) |
2 (1、2) |
< 0.001 |
3 (2、3) |
2 (1、2) |
< 0.001 |
| ψ |
128±40 |
161±37 |
120±36 |
< 0.001 |
156±38 |
118±36 |
< 0.001 |
| 沙发 |
3 (2、5) |
6 (9) |
3 (2、4) |
< 0.001 |
6 (4、8) |
3 (2、4) |
< 0.001 |
| qSOFA |
2 (1、2) |
3 (2、3) |
1 (1、2) |
< 0.001 |
2 (2、3) |
1 (1、2) |
< 0.001 |
| 乳酸(更易/ L) |
1.4 (1.1,2.1) |
1.9 (1.3,4.2) |
1.4 (1.1,1.8) |
< 0.001 |
2.3 (1.4,4.1) |
1.3 (1.0,1.6) |
< 0.001 |
|
|
|
数据了n,n(%),或中位数(问
l,问
U)。帽子:社区获得性肺炎;MV:机械通气;NMV: nonmechanical通风;艾德:急诊科;SCAP:重症社区获得性肺炎;NSCAP:长程社区获得性肺炎;慢性阻塞性肺病:慢性阻塞性肺疾病;CDVD:心血管疾病;CBVD:脑血管疾病; CRD: chronic renal disease; HBD: hepatobiliary disease; WBC: white blood cell; HGB: hemoglobin; HCT: hematocrit; PLT: platelet; ALB: albumin; CREA: creatinine; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; CURB65: confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, blood pressure < 90 mmHg systolic and/or ≤60 mmHg diastolic, and age ≥ 65 years; CRB65: confusion, respiratory rate ≥ 30/min, blood pressure < 90 mmHg systolic and/or ≤60 mmHg diastolic, and age ≥ 65 years; PSI: pneumonia severity index; SOFA: sequential organ failure assessment; qSOFA: quick sequential organ failure assessment.
|
